Zydus Lifesciences Limited — Updates, 16-04-2025: Press Release

Zynext Ventures, the venture capital arm of Zydus Lifesciences, has invested in Feldan Therapeutics, a Canadian company focused on intracellular drug delivery innovations. Feldan's proprietary Shuttle peptide technology facilitates the targeted delivery of biomolecules into cells, with their lead candidate, FLD-103, aimed at treating basal cell carcinoma (BCC) lesions through non-surgical means. This approach seeks to enhance patient quality of life by providing an effective targeted therapy. Additionally, Feldan is developing a pulmonary program to address respiratory diseases utilizing the Shuttle's capabilities. Zydus Lifesciences' MD, Dr. Sharvil Patel, emphasized the company's commitment to supporting novel therapeutics that fill critical healthcare gaps. This strategic investment aligns with Zynext Ventures' goal of integrating disruptive innovations into their portfolio. The partnership is set to accelerate the development of impactful next-generation therapies, marking an important progress in addressing significant drug delivery challenges within healthcare.